Business
ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027
LYON, France, April 21, 2026--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the establishment of a shareholder loan agreement with Vester Finance, repayable in new shares, with an option for the Company to repay in cash under certain conditions.
About this update from Adocia Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/780b2e613b0d0d192aced21308782395"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AwdHPs.JyzLMvVHUxT_Irg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4OA--/https://media.zenfs.com/en/business-wire.com/780b2e613b0d0d192aced21308782395","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/FffF7SUvAAqRwX92PZ1jpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA-/https://media.zenfs.com/en/business-wire.com/780b2e613b0d0d192aced21308782395","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Signing of a two-year shareholder loan agreement for up to €6.0 million, of which €1.5 million paid upon signing, repayable in new shares representing up to 7.6% of the Company’s share capital or in cash","length":203,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This shareholder operation secures the cash runway until beginning Q2 2027","length":74,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":277,"olType":false},{"type":"text","content":"LYON, France, April 21, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced the establishment of a shareholder loan agreement with Vester Finance, repayable in new shares, with an option for the Company to repay in cash under certain conditions.","length":418,"tagName":"p"},{"type":"text","content":""We are delighted to complete this transaction proposed by Vester Finance as he is the largest shareholder after the Soula co-founders and has been involved in most of our financing transactions and fundraising campaigns over the past four years. In addition, Vester Finance has increased his equity position since the beginning of 2026, currently holding 4.2% of the share capital," says Olivier Soula, Chief Executive Officer of Adocia. "We are extending our cash runway with this guaranteed optional financing fa...